Testing CAR T-cell therapy for cancer that has spread to the linings of the chest, belly, or brain
Original title: Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in a small number of people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a new cell therapy for cancer that has spread to body linings.
Who this trial is for. This trial is for people whose solid tumor has spread to the lining of the chest, the belly, or the brain and spinal cord. It tests CAR T-cells made to attack the cancer in more than one way, given as a single infusion into that area.
Where it stands. This trial has not reported results. It is first checking side effects and how much of the cell therapy people can safely take. It also looks at whether tumors shrink and how long the cells last in the body. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: There is no proof yet that this helps. It is an early test to see if it is safe enough to keep studying. Someone who fits this kind of study could ask their care team about it.
What it doesn't mean: This does not mean a new treatment is ready. A trial is a test, not proven care. Being in one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.